Record #3802
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma
Original paper date
Jan 1, 2016
Original DOI
Country
Open access
No
Article type
Citation lifecycle
How this paper is being cited
Pre-retraction
0
Same day
0
Post-retraction
21
% post-retraction
100.0%
~0.0 citations/yr before retraction · ~2.0 citations/yr after
— citing papers
Who is still citing this work
Loading…